Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Rapamycin + PDL in Sturge-Weber Syndrome
NCT02080624Phase 2Completed
- Sponsor
- Universidad de Navarra
- Start
- Jan 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of sirolimus in Sturge-Weber syndrome (SWS), sponsored by Universidad de Navarra. Primary endpoints: Change from baseline in morphologic, chromatographic and spectrometric scores at 18 weeks and Histological response at 12 weeks. Started Jan 2011; status: completed.
02
Drugs
sirolimus
03
Conditions
Sturge-Weber syndrome (SWS)
Beyond the preview
Go deeper on NCT02080624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080624.